Divi reported Rs 15.5 billion capex in H1 FY26 and expects more than Rs 20 billion for FY26, indicating aggressive expansion and long-term growth planning.(Source: Unsplash) Divi’s Laboratories delivered better-than-expected performance in Q2 with a 4%/10%/10% beat on revenue/Ebitda/PAT. While gross margin has been steady for the past eight quarters, Divi's Labs has delivered improved Ebitda margin YoY as well as QoQ, led by better operating leverage.

To continue reading this story You must be an existing Premium User Already a Premium User? Sign In

See Full Page